Frequent fusion of the CRTCI and MAML2 genes in clear cell variants of cutaneous hidradenomas

Genes Chromosomes and Cancer

Volumn 46, Issue 6, 2007, Pages 559-563

  Winnes, Marta ^a   Mölne, Lena ^a   Suurküla, Mart ^a   Andrén, Ywonne ^a   Persson, Fredrik ^a   Enlund, Fredrik ^a   Stenman, Göran ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GENE PRODUCT; HYBRID PROTEIN; MESSENGER RNA; PROTEIN CRTC1; PROTEIN MAML2; UNCLASSIFIED DRUG; MECT1 MAML2 FUSION PROTEIN, HUMAN; MECT1-MAML2 FUSION PROTEIN, HUMAN; ONCOPROTEIN;

ADULT; AGED; ARTICLE; CANCER GENETICS; CELL STRUCTURE; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CRTC1 GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION REGULATION; GENE FUSION; GENE INDUCTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HIDRADENOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MAML2 GENE; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; SWEAT GLAND TUMOR;

ADENOMA, SWEAT GLAND; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SWEAT GLAND NEOPLASMS;

EID: 34247474279     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20440     Document Type: Article

References (20)

1. Abenoza P, Ackerman AB. 1990. Hidradenomas. In: Abenoza P, Ackerman AB, editors. Neoplasms with Eccririe Differentiation. Philadelphia: Lea and Febiger, pp. 311-350.
2. Behboudi A, Enlund F, Winnes M, Andren Y, Nordkvist A, Leivo I, Flaberg E, Szekely L, Makitie A, Grenman R, Mark J, Stenman G. 2006. Molecular classification of mucoepidermoid carcinomas-prognostic significance of the MECT1-MAML2 fusion oncogene. Genes Chromosomes Cancer 45:470-481.
3. Behboudi A, Winnes M, Gorunova L, van den Oord JJ, Mertens F, Enlund F, Stenman G. 2005. Clear cell hidradenoma of the skin-a third tumor type with a t(11;19)-associated TORC1-MAML2 gene fusion. Genes Chromosomes Cancer 43:202-205.
4. Brenn T, McKee PH. 2005. Tumors of the sweat glands. In: McKee PH, Calonje E, Granter SR, editors. Pathology of the Skin with Clinical Correlations, 3rd ed. St. Louis: Elsevier Mosby, pp. 1589-1661.
5. Bullerdiek J, Haubrich J, Meyer K, Bartnitzke S. 1988. Translocation t(11;19)(q21;p13.1) as the sole chromosome abnormality in a cystadenolymphoma (Warthin's tumor) of the parotid gland. Cancer Genet Cytogenet 35:129-132.
6. Coxon A, Rozenblum E, Park YS, Joshi N, Tsurutani J, Dennis PA, Kirsch IR, Kaye FJ. 2005. Mect1-Mam12 fusion oncogene linked to the aberrant activation of cyclic AMP/CREB regulated genes. Cancer Res 65:7137-7144.
7. Enlund F, Behboudi A, Andren Y, Oberg C, Lendahl U, Mark J, Stenman G. 2004. Altered Notch signaling resulting from expression of a WAMTP1-MAML2 gene fusion in mucoepidermoid carcinomas and benign Warthin's tumors. Exp Cell Res 292:21-28.
8. Gianotti R, Alessi E. 1997. Clear cell hidradenoma associated with the folliculo-sebaceous-apocrine unit. Histologic study of five cases. Am J Dermatopathol 19:351-357.
9. Gorunova L, Mertens F, Mandahl N, Jonsson N, Persson B, Heim S, Mitelman F. 1994. Cytogenetic heterogeneity in a clear cell hidradenoma of the skin. Cancer Genet Cytogenet 77:26-32.
10. Heenan PJ, Elder DE, Sobin LH. 1996. Histological Typing of Skin Tumors. World Health Organization International Histological Classification of Tumours, 2nd ed. Berlin: Springer-Verlag, p. 54.
11. Komiya T, Park Y, Modi S, Coxon AB, Oh H, Kaye FJ. 2006. Sustained expression of Mect1-Mam12 is essential for tumor cell growth in salivary gland cancers carrying the t(11;19) translocation. Oncogene 25:6128-6132.
12. Larsen WJ. 2001. Human Embryology, 3rd ed. Philadelphia: Churchill Livingstone, pp. 351-378, 465-480.
13. Mark J, Dahlenfors R, Stenman G, Nordquist A. 1989. A human adenolymphoma showing the chromosomal aberrations del (7)(p12p14-15) and t(11;19)(q21;p12-13) . Anticancer Res 9:1565-1566.
14. Nordkvist A, Gustafsson H, Juberg-Ode M, Stenman G. 1994. Recurrent rearrangements of 11q14-22 in mucoepidermoid carcinoma. Cancer Genet Cytogenet 74:77-83.
15. Okabe M, Miyabe S, Nagatsuka H, Terada A, Hanai N, Yokoi M, Shimozato K, Eimoto T, Nakamura S, Nagai N, Hasegawa Y, Inagaki H. 2006. MECT1-MAML2 fusion transcript defines a favorable subset of mucoepidermoid carcinoma. Clin Cancer Res 12:3902-3907.
16. Riedlinger WF, Hurley MY, Dehner LP, Lind AC. 2005. Mucoepidermoid carcinoma of the skin: A distinct entity from adenosquamous carcinoma: A case study with a review of the literature. Am J Surg Pathol 29:131-135.
17. Stenman G. 2005. Fusion oncogenes and tumor type specificity - Insights from salivary gland tumors. Semin Cancer Biol 15:224-235.
18. Tonon G, Modi S, Wu L, Kubo A, Coxon AB, Komiya T, O'Neil K, Stover K, El-Naggar A, Griffin JD, Kirsch IR, Kaye FJ. 2003. t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. Nat Genet 33:208-213.
19. Winnes M, Enlund F, Mark J, Stenman G. 2006. The MECT1-MAML2 gene fusion and benign Warthin's tumor: Is the MECT1-MAML2 gene fusion specific to mucuepidermoid carcinoma? J Mol Diagn 8:394-395.
20. Wu L, Liu J, Gao P, Nakamura M, Cao Y, Shen H, Griffin JD. 2005. Transforming activity of MECT1-MAML2 fusion oncoprotein is mediated bv constitutive CREB activation. EMBO J 24:2391-2402.